Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study
2024
Correction of Data in Study on Romiplostim for Aplastic Anemia
Erratum
Author Information
Author(s): Mitani K, Lee JW, Jang JH
Primary Institution: The American Society of Hematology
Conclusion
This erratum corrects specific data in a previous publication regarding the efficacy and safety of romiplostim in refractory aplastic anemia.
Supporting Evidence
- In supplemental Table 3, a correction was made for Patient #18's duration of platelet response.
- In supplemental Figure 4, the label was corrected to reflect the number at risk.
Takeaway
This is a correction to a previous study, fixing some mistakes in the data presented.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website